Biogen Cash Flow | StatInvestor

Health Care & Life Sciences » Biotechnology | Biogen Inc.

Biogen Inc. | Cash Flow

Fiscal year is January-December. All values USD Millions.

2013

2014

2015

2016

2017

2018

Net Income before Extraordinaries

1,862

2,942

3,593

3,696

2,670

4,474

Depreciation, Depletion & Amortization

532

637

600

683

1,081

651

Other Funds

454

555

Funds from Operations

2,258

3,426

4,292

4,449

4,316

5,788

Changes in Working Capital

484

576

235

400

Net Operating Cash Flow

2,345

2,942

3,716

4,522

4,551

6,188

Capital Expenditures

3,509

288

643

728

1,843

Purchase/Sale of Investments

1,912

864

2,802

534

211

Net Investing Cash Flow

1,605

1,543

4,554

2,485

2,963

Issuance/Reduction of Debt, Net

452

5,928

561

Net Financing Cash Flow

717

756

986

988

2,380

Net Change in Cash

602

103

1,019

753

Free Cash Flow

2,099

2,654

3,073

3,906

3,684

Deferred Taxes & Investment Tax Credit

245

308

146

175

108

Net Assets from Acquisitions

199

Other Sources

Change in Capital Stock

334

832

4,946

956

1,365

Exchange Rate Effect

Other Uses

391

910

1,223

1,331

About Biogen

View Profile

Address	225 Binney Street Cambridge Massachusetts 02142 United States
Employees	-
Website	http://www.biogen.com
Updated	07/08/2019
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.